← Eichor
Condition: Refractory Myasthenia Gravis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Refractory Myasthenia Gravis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07717281Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University General Hospital · NCT07022197Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
NA · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT07413835Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in
EARLY_Phase 1 · 1 location(s) · Tianjin Huanhu Hospital · NCT06939166Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Phase 1 · 1 location(s) · Ting Chang, MD · NCT06371040A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Phase 1 · 6 location(s) · Kite, A Gilead Company · NCT07304154GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
EARLY_Phase 1 · 1 location(s) · Daishi Tian · NCT07058298Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous Sys
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT04561557Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
NA · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07470151Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media
Phase 1 · 1 location(s) · Tongji Hospital · NCT07526493A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized M
Phase 1 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06688435A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Phase 1 · 1 location(s) · RenJi Hospital · NCT06249438CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT07337785Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Phase 1 · 1 location(s) · Polina Stepensky · NCT07085676A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms
Phase 1 · 35 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06220201
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.